Welcome to our dedicated page for Co-Diagnostics news (Ticker: CODX), a resource for investors and traders seeking the latest updates and insights on Co-Diagnostics stock.
Co-Diagnostics, Inc. (NASDAQ: CODX) is a molecular diagnostics company that develops, manufactures and markets technologies for tests designed to detect and analyze nucleic acid molecules (DNA or RNA). Its news flow centers on progress in molecular assay development, regulatory pathways for its Co-Dx PCR platform, intellectual property milestones, joint ventures, and capital markets activity.
Readers following CODX news can expect regular updates on the company’s point-of-care Co-Dx PCR platform, including the Co-Dx PCR Home and Co-Dx PCR Pro instruments, associated tests, and mobile app, all of which the company notes are subject to regulatory review and not yet available for sale. Recent announcements have covered clinical evaluations for the Co-Dx PCR Flu A/B, COVID-19, RSV upper respiratory multiplex test kit, preclinical and planned clinical performance studies for tuberculosis (MTB) and HPV tests on the platform, and the development of a proprietary sample preparation instrument for point-of-care use.
Co-Diagnostics also issues news about its joint ventures and international collaborations. Updates include activities of CoSara Diagnostics Pvt. Ltd. in India, such as participation in regional conferences and capacity-building workshops, and the formation of CoMira Diagnostics with Arabian Eagle Manufacturing to research, develop, manufacture, assemble, distribute and commercialize Co-Dx technologies in the Kingdom of Saudi Arabia and 18 MENA nations.
Investors and observers will find coverage of intellectual property developments, such as the grant of Australian Patent No. AU2022270084A1 for the Co-Dx PCR platform, as well as corporate and financing events disclosed through press releases and SEC filings. News items may also highlight the company’s AI business unit and presentations at industry conferences on portable, cloud-connected PCR diagnostics and AI integration. This page aggregates these updates so that users can review CODX-related announcements and regulatory communications in one place.
Co-Diagnostics, Inc. (Nasdaq: CODX) is participating in the 22nd MEDEXPO Africa 2022 in Nairobi, Kenya from June 9-11. This significant event showcases over 30 countries' medical technology solutions, aiming at buyers seeking innovative products and services. This marks Co-Dx's first trade show in Africa, enhancing its initiative to promote COVID-19 and other infectious disease tests across the continent. Notably, the company has completed the design of a PCR test for monkeypox. Interested attendees can find Co-Dx at Booth #124.
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) has completed the principal design of a PCR test for the monkeypox virus, amid a multi-country outbreak. The test will leverage the Company's patented CoPrimer™ technology and proprietary software system. CEO Dwight Egan emphasized the need for prompt action against potential outbreaks, highlighting Co-Dx's mission to enhance access to affordable, high-quality molecular testing globally. The World Health Organization reported monkeypox cases in 18 non-endemic countries since May 13, 2022.
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) announced its participation at the H.C. Wainwright & Co. 2022 Global Investment Conference, scheduled for May 23-26 in Miami, Florida. CEO Dwight Egan will present on May 25 at 1:30 PM ET, discussing the company's recent performance and its new Co-Dx PCR Home Diagnostic Platform. Egan highlighted Florida's significance as a market, contributing over $28 million in revenue since the pandemic began. The conference aims to engage institutional investors and industry professionals.
Co-Diagnostics, Inc. (NASDAQ: CODX) reported record first-quarter revenue of $22.7 million and a diluted EPS of $0.34 for the period ending March 31, 2022. Revenue growth was driven mainly by sales of the Logix Smart™ COVID-19 Test. Gross profit rose to $19.4 million, reflecting an 85.5% gross margin. However, operating income slightly decreased to $9.8 million due to increased R&D expenses. Cash reserves increased to $97.4 million, providing a strong foundation for future growth. Despite positive results, management highlighted challenges in forecasting future COVID-19 test sales due to changing market conditions.
Co-Diagnostics, Inc. (Nasdaq: CODX) announced its participation at the Medical Fair Brasil from May 3-6, 2022, in São Paulo. This international exhibition focuses on hospital and diagnostic supplies, attracting key healthcare professionals. Co-Dx will showcase its innovative molecular diagnostic technologies, including a new point-of-care rapid PCR diagnostics platform. The event offers an opportunity for Company representatives to connect directly with decision-makers in healthcare, enhancing product visibility and potential sales.
Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company, announced that it will release its first quarter 2022 financial results on May 12, 2022, after market close. A conference call and webcast will follow at 4:30 p.m. EDT to discuss these results with analysts and investors. Key management, including CEO Dwight Egan and CFO Brian Brown, will participate in the call. The call will be accessible via the company's website and will also be recorded for later viewing.
Co-Diagnostics, Inc. (Nasdaq: CODX) will host a booth at the 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Lisbon, Portugal, from April 23-26, 2022. This congress will gather over 14,000 experts to discuss advances in clinical microbiology and infectious diseases. Co-Dx aims to engage potential international customers and showcase its upcoming rapid PCR diagnostics platform. The event will feature both onsite and online sessions, enhancing accessibility for attendees. For more details, visit ECCMID's official site.
Co-Diagnostics, Inc. (Nasdaq: CODX) announced that its joint venture, CoSara Diagnostics, has received clearance from India's Central Drugs Standard Control Organization (CDSCO) to manufacture and sell the SARAQ™ Hepatitis C Viral Load Kit as an in vitro diagnostic. This new real-time PCR test is crucial for assessing responses to antiviral treatments for Hepatitis C, a disease causing nearly 300,000 deaths annually. With over 58 million people affected globally, the test represents an essential addition to CoSara's growing diagnostics portfolio, enhancing patient care in regions with high disease burdens.
Co-Diagnostics, Inc. (NASDAQ: CODX) reported record full-year revenue of $97.9 million for 2021, up $23.3 million year-over-year, driven by sales of Logix Smart™ COVID-19 tests. Gross profit increased to $86.3 million, representing 88.2% of revenue. Net income was $36.7 million, down from $42.5 million in 2020. The company completed two strategic acquisitions and revealed a new at-home PCR diagnostic platform. Looking ahead, Q1 2022 revenue is projected between $21.0 million and $22.0 million.
Co-Diagnostics, Inc. (Nasdaq: CODX), a leader in molecular diagnostics, will present its YourTest™ PCR device at the 3rd Annual MarketsandMarkets Infectious Disease Diagnostics and Molecular Diagnostics Conference on March 23-24, 2022, in London, England. CEO Dwight Egan will discuss the device on March 23rd at 14:00 GMT. The conference focuses on advancements in diagnostic testing for medical viruses, particularly Covid-19. Co-Diagnostics aims to enhance global access to care and innovation in diagnostics.
FAQ
What is the current stock price of Co-Diagnostics (CODX)?
What is the market cap of Co-Diagnostics (CODX)?
